Thursday, July 26, 2012
California stem cell agency chairman J.T. Thomas has raised the possibility of sending some of the disease team applications back for additional review if the board feels that is necessary to consider new information and resolve scientific disputes.
Thomas discussed such a move at the beginning of the discussion of the $243 million disease team round. Nine out of 15 rejected applicants have appealed to the full board. Some have presented new information. Others have disputed the scientific work of reviewers.
The board used such a referral process for one application in the past. That grant was ultimately approved.Sphere: Related Content